CO
COEPW
Z Squared Inc.
No data for this timeframe.
Vol
Inst. Holders1 funds
Inst. Value$1.00
Inst. Activity1 buys / 1 sells
SEC Reports3
Recent Activity
Apr 30, 2026
SEC
Christopher Ryan Schadel filed an initial statement of beneficial ownership (Form 3) with the SEC, disclosing his role a
3 — Impact 2/10
Apr 24, 2026
SEC
Nasdaq has filed a Form 25-NSE to delist the warrants of Coeptis Therapeutics Holdings, Inc. (COEPW) due to their maturi
25-NSE — Impact 3/10
Apr 8, 2026
SEC
Coeptis Therapeutics announced that Nasdaq has approved, subject to customary conditions, the listing of the post-merger
8-K — Impact 6/10
Inst.
UBS Group AG — DOUBLED
678 shares ($15.00)
Inst.
WELLS FARGO & COMPANY/MN — TRIM
100 shares ($2.00)
Latest Reports
NEUTRAL
3
2/10
Christopher Ryan Schadel filed an initial statement of beneficial ownership (Form 3) with the SEC, disclosing his role a
Apr 30, 2026
NEUTRAL
25-NSE
3/10
Nasdaq has filed a Form 25-NSE to delist the warrants of Coeptis Therapeutics Holdings, Inc. (COEPW) due to their maturi
Apr 24, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| WELLS FARGO & COMPANY/MN | $1.00 | TRIM |
1 institutional holders with $1.00 total value (100 shares) as of 2025-Q4. Top holders: WELLS.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | WELLS FARGO & COMPANY/MN | 100 | $1.00 | 100.0% | TRIM -50.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| UBS Group AG | DOUBLED | 44 | 678 | +1440.9% | $15.00 | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | TRIM | 200 | 100 | -50.0% | $2.00 | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 2 neutral. Avg impact: 3.7/10.
NEUTRAL
3
2/10
Christopher Ryan Schadel filed an initial statement of beneficial ownership (Form 3) with the SEC, d
Apr 30, 2026
NEUTRAL
25-NSE
3/10
Nasdaq has filed a Form 25-NSE to delist the warrants of Coeptis Therapeutics Holdings, Inc. (COEPW)
Apr 24, 2026
MIXED
8-K
6/10
Coeptis Therapeutics announced that Nasdaq has approved, subject to customary conditions, the listin
Apr 8, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.